PIRH2在肾细胞癌中的表达及其意义  

Expression and clinical significance of PIRH2 in renal cell carcinoma

作　　者：王国栋[1] 党亚正[1] 

机构地区：[1]解放军第三二三医院综合内科,陕西西安710054

出　　处：《西部医学》2014年第3期280-282,共3页Medical Journal of West China

基　　金：陕西省自然科学基金(CWS105B07)

摘　　要：目的检测PIRH2蛋白在肾细胞癌中的表达,探讨其与临床病理特征间的关系。方法利用免疫组化SP法分别检测肾癌及对应癌旁正常肾组织(各56例)中PIRH2的表达情况,以软件SPSS 17.0进行统计分析。结果 PIRH2在肾癌组织和癌旁正常肾组织中的阳性表达率分别为55.4%和16.1%,差异有统计学意义(P<0.05)。肾癌中PIRH2的高表达与临床分期、病理分化程度有关(P<0.05),而与病理类型、性别、年龄等无关(P>0.05)。结论 PIRH2可能参与了肾癌的发生发展过程,靶向抑制PIRH2表达有望成为晚期肾癌治疗的新方法。Objective To investigate the expression level and clinical significance of p53-induced RING-H2 protein （PIRH2） in renal cell carcinoma （RCC）. Methods Expression of PIRH2 protein was analyzed by immunohistochemistry in 56 RCC cancer tissues and their adjacent normal renal tissues. Results Immunohistochemistry analysis revealed that the positive rate of PIRH2 in RCC tissues was significant higher than that of in normal tissues （55.4% versus 16.1 %）. Over expression of PIRH2 was associated with the clinical stage, pathological differentiation while were not correlated with pathological types, age and gender （P〉0.05）. Conclusion Dysregulated expression of PIRH2 may play important roles in kidney carcinogenesis and progression. Inhibition of PIRH2 is a promising therapeutic approach for RCC.

关 键 词：肾细胞癌 PIRH2 免疫组织化学 

分 类 号：R737.11[医药卫生—肿瘤] R446.8[医药卫生—临床医学]